Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA -positive chronic eosinophilic leukemia: implications for optimal dosing

Amy D. Klion, Jamie Robyn, Irina Maric, Weiming Fu, Laura Schmid, Steven Lemery, Pierre Noel, Melissa A. Law, Marilyn Hartsell, Cheryl Talar-Williams, Michael P. Fay, Cynthia E. Dunbar, Thomas B. Nutman

Blood (2007) 110 (10): 3552–3556.

https://doi.org/10.1182/blood-2007-07-100164

Published: 2007

Journal Articles

Systemic Mastocytosis with Eosinophilia: A Novel Diagnostic Approach To Distinguish Imatinib-Resistant Kit D816V-Associated Mast Cell Disease from Imatinib-Sensitive FIP1L1/PDGFRA-Associated Hypereosinophilic Syndrome.

Todd M. Wilson, Irina Maric, Amy D. Klion, Cem Akin, Melody Carter, Weiming Fu, Jennifer Stoddard, Linda Scott, Arnold Kirshenbaum, Michael Fay, Thomas B. Nutman, Pierre Noel, Dean D. Metcalfe, Jamie Robyn

Blood (2006) 108 (11): 2683.

https://doi.org/10.1182/blood.V108.11.2683.2683

Published: 2006

Journal Articles

Detection of c-Kit Mutation in Peripheral Blood vs. Bone Marrow Aspirates in Patients with Systemic Mastocytosis: Comparison Study of Pathological and Clinical Laboratory Findings in Patients with and without Detectable c-Kit Mutation in the Peripheral Blood.

Irina Maric, MD, Jamie Robyn, M.D., Ph.D., Weiming Fu, M.D., Jennifer Stoddard, Dean D. Metcalfe, M.D., Pierre Noel, M.D.

Blood (2006) 108 (11): 3596.

https://doi.org/10.1182/blood.V108.11.3596.3596

Published: 2006

Journal Articles

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

Amy D. Klion, Jamie Robyn, Cem Akin, Pierre Noel, Margaret Brown, Melissa Law, Dean D. Metcalfe, Cynthia Dunbar, Thomas B. Nutman

Blood (2004) 103 (2): 473–478.

https://doi.org/10.1182/blood-2003-08-2798

Published: 2004

Journal Articles

HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome

Yogen Saunthararajah, Ryotaro Nakamura, Jun-Mo Nam, Jamie Robyn, Fausto Loberiza, Jaroslaw P. Maciejewski, Toni Simonis, Jeffrey Molldrem, Neal S. Young, A. John Barrett

Blood (2002) 100 (5): 1570–1574.

https://doi.org/10.1182/blood.V100.5.1570.h81702001570_1570_1574

Published: 2002

NARROW

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA -positive chronic eosinophilic leukemia: implications for optimal dosing

Systemic Mastocytosis with Eosinophilia: A Novel Diagnostic Approach To Distinguish Imatinib-Resistant Kit D816V-Associated Mast Cell Disease from Imatinib-Sensitive FIP1L1/PDGFRA-Associated Hypereosinophilic Syndrome.

Detection of c-Kit Mutation in Peripheral Blood vs. Bone Marrow Aspirates in Patients with Systemic Mastocytosis: Comparison Study of Pathological and Clinical Laboratory Findings in Patients with and without Detectable c-Kit Mutation in the Peripheral Blood.

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome

Email alerts

ASH Publications

American Society of Hematology

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA -positive chronic eosinophilic leukemia: implications for optimal dosing

Systemic Mastocytosis with Eosinophilia: A Novel Diagnostic Approach To Distinguish Imatinib-Resistant Kit D816V-Associated Mast Cell Disease from Imatinib-Sensitive FIP1L1/PDGFRA-Associated Hypereosinophilic Syndrome.

Detection of c-Kit Mutation in Peripheral Blood vs. Bone Marrow Aspirates in Patients with Systemic Mastocytosis: Comparison Study of Pathological and Clinical Laboratory Findings in Patients with and without Detectable c-Kit Mutation in the Peripheral Blood.

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only